Eli Lilly (LLY) On Foundayo Launch And Higher Outlook Faces A Rich Valuation
Eli Lilly (LLY) has moved further into obesity and diabetes care with the UK launch of its once daily oral GLP-1 pill Foundayo, orforglipron, shortly after lifting its full year outlook.
See our latest analysis for Eli Lilly.
The launch of Foundayo comes during a strong run for Eli Lilly’s stock, with a 90 day share price return of 17.91% and a 1 year total shareholder return of 81.69%. This indicates momentum that has built rather than faded over multiple years.
If you are interested in how other healthcare companies are using AI in treatment and diagnostics, now could be a useful moment to scan the 41 healthcare AI stocks.
Eli Lilly’s rapid share price move and fresh products like Foundayo now leave investors weighing how much of the story is already in the price versus what the current valuation still assumes is ahead.
Most Popular Narrative: 15% Undervalued
The most followed valuation narrative for Eli Lilly points to a fair value above the last close of $1,255.40, which suggests a pricing gap that some investors view as meaningful.
The model uses four inputs to arrive at the fair value: growth rate, which has been adjusted to 18% to reflect reality rather than the overly conservative 12.71% default; a future PE ratio of 30 times earnings in 2031, down from today's 39 times, which accounts for the natural compression in valuation multiples as a company matures and grows larger; a discount rate of 7.5%, slightly above the default of 6.98%, to account for the pipeline risks that still exist; and earnings by 2031 of approximately $48 to $50 billion, above the model's $41.5 billion, because at 18% growth and stable margins, that is where the numbers land.
Curious how Eli Lilly gets from today’s earnings to that higher fair value range? The narrative leans on profit expansion, firm margins and a rich future multiple. The exact mix of those inputs is what really shifts the valuation story.
Result: Fair Value of $1,477.03 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Eli Lilly’s story could shift quickly if pricing pressure on GLP 1 drugs intensifies or key pipeline trials deliver weaker than expected outcomes.
Find out about the key risks to this Eli Lilly narrative.
Another View on Eli Lilly’s Valuation
While the most popular Eli Lilly narrative leans on a detailed earnings model, the market price also reflects what investors pay for each dollar of current earnings. On this measure, Eli Lilly trades on a P/E of 41.9x, compared with 16.8x for the US pharmaceuticals industry and a fair ratio of 40.5x that the market could move towards.
This P/E is below the peer average of 50.3x, which hints at some relative value, yet it still sits above the fair ratio, which implies less room for error if sentiment cools. The question for investors is whether Eli Lilly’s current growth and pipeline justify paying this much more for each dollar of earnings.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With Eli Lilly attracting both optimism and caution in equal measure, it makes sense to move quickly and weigh the evidence for yourself. To see how the positives and risks balance out, review the 3 key rewards and 1 important warning sign
Looking for more investment ideas beyond Eli Lilly?
If Eli Lilly has sharpened your interest in new opportunities, do not stop here. Use these focused stock lists to spot potential ideas you might otherwise miss.
- Target potential mispricing by scanning companies that feature in the 48 high quality undervalued stocks.
- Strengthen your income stream by reviewing stocks highlighted in the 12 dividend fortresses.
- Prioritise resilience by focusing on companies surfaced through the 75 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com